Pharmachemie Cisplatin ANDA Should Get 180-Day Exclusivity As First To File

Generic exclusivity should be granted to the first paragraph IV ANDA holder to file, regardless of subsequent changes to the application's certification or to the patent challenged, Pharmachemie B.V. asserted in a June 9 citizen's petition maintaining its right to 180 days of exclusivity for generic cisplatin.